<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02398552</url>
  </required_header>
  <id_info>
    <org_study_id>BCH-RCC-150212</org_study_id>
    <nct_id>NCT02398552</nct_id>
  </id_info>
  <brief_title>A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.</brief_title>
  <official_title>A Randomized Phase II Trila of Sunitinib Four-weeks on/Two-weeks Off Versus Two-weeks on/One-week Off as First Line Therapy in Metastatic Renal Cell Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sunitinib given at 50 mg/day on schedule 4/2 (4 weeks on treatment, 2 weeks off) is the
      standard care for first-line treatment of metastatic renal cell carcinoma, but the schedule
      was reported with a high rate of dose reduction and dose discontinuation because of the
      safety profile. So investigators conducte this randomized, multi-center phase II study to
      determine whether a sunitinib regimen of 50 mg/day 2-weeks on/1-week off could provide the
      same efficacy in terms of progression-free survival, objective response, and overall
      survival, while reducing drug-related toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sunitinib given at 50 mg/day on schedule 4/2 (4 weeks on treatment, 2 weeks off) is the
      standard care for first-line treatment of metastatic renal cell carcinoma, but the schedule
      was reported with a high rate of dose reduction and dose discontinuation because of the
      safety profile. Sunitinib 50mg/day on schedule 2/1 (2 weeks on treatment, 1 weeks off) was
      reported to be associated with significantly decrease toxicities in patients who initially
      experienced grade 3 or greater toxicity on the schedule 4/2 and could extend treatment
      duration considerably. Through this research, we would like to explore whether the schedule
      2/1 of sunitinib 50 mg/day as first line therapy could provide the same efficacy as standard
      schedule 4/2 in terms of progression-free survival, objective response, and overall survival,
      while reducing drug-related toxicity in metastatic renal cell carcinoma patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progress-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Time from enrollment to the dates of disease progression,death from any cause or last tumor assessment reported between date of first patient enrollment until March 2017 cut off date</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients who can get complete response, partial response.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sunitinib 50mg/day schedule 4/2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sunitinib 50mg/day 4 weeks on/2 weeks off per 6 weeks till disease progression or intolerable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sunitinib 50mg/day schedule 2/1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib 50mg/day 2 weeks on/1 week off per 6 weeks till disease progression or intolerable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.</description>
    <arm_group_label>Sunitinib 50mg/day schedule 4/2</arm_group_label>
    <arm_group_label>Sunitinib 50mg/day schedule 2/1</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age≥18 years, ≤75 years, male or female

          -  Advanced renal cell carcinoma is diagnosed histologically or pathologically

          -  Treatment naive at diagnosed

          -  At least one measurable tumor lesion (Response Evaluation Criteria In Solid Tumors)

          -  Eastern Cooperative Oncology Group（ECOG) performance scale is 0 or 1

          -  The expected life span is ≥12 weeks

          -  No contraindications for targeted therapy, with enough liver function and renal
             function and normal ECG recording Peripheral hemogram: neutrophil≥1.5×109/L,
             Plt≥100×109/L, Hgb≥90g/L Renal function: serum creatinine≤1.5 folds the upper limit of
             normal (ULN) For patients with non-metastatic liver dysfunction:alanine
             aminotransferase and aspartate aminotransferase≤2.5 ULN, For patients with metastatic
             liver dysfunction: alanine aminotransferase and aspartate aminotransferase≤5 ULN

          -  The patients participate voluntarily and have signed the informed consent form

        Exclusion Criteria:

          -  Patients who have received any systemic therapy including targeted
             therapy,immunotherapy,chemotherapy etc at diagnosed.

          -  Pregnant and lactating women, or female patients of child-bearing age without taking
             contraceptive measures

          -  Patients with severe acute infection without being controlled effectively or having
             pyogenic and chronic infections with persistently unhealed wounds

          -  Past history of serious heart diseases, including: cardiac function classification
             ≥NYHA class II, unstable angina pectoris, myocardial infarction, arrhythmia requiring
             anti-arrhythmic drug therapy (excluding β-blockers or digoxin), and uncontrolled
             hypertension

          -  Patients with a history of HIV infection or active phase of chronic hepatitis B/C

          -  negative imaging examination result 4 weeks prior to enrollment)

          -  Epilepsy patients requiring drug therapy (e.g. steroids or antiepileptic drugs)

          -  A history of allogeneic organ transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Guo, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chuanliang Cui, MD</last_name>
    <phone>0086-10-88196951</phone>
    <email>1008ccl@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Guo, MD,PHD</last_name>
    <phone>0086-10-88196317</phone>
    <email>guoj307@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese acadamy of medical science cancer institute &amp; hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Changling Li, MD</last_name>
      <phone>0086-10-67781331</phone>
      <email>changllss@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Changling Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhisong He, MD</last_name>
      <phone>0086-10-83572211</phone>
      <email>wyj7074@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Zhisong He, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuanliang Cui, MD</last_name>
      <phone>0086-10-88196951</phone>
      <email>1008ccl@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jun Guo, MD,PHD</last_name>
      <phone>0086-10-88196317</phone>
      <email>guoj307@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jun Guo, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen university cancer center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fangjian Zhou, MD</last_name>
      <phone>0086-20-87343088</phone>
      <email>zhoufj@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Fangjian Zhou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dingwei Ye, MD</last_name>
      <phone>0086-21-64175590</phone>
      <email>dwye@163.com</email>
    </contact>
    <investigator>
      <last_name>Dingwei Ye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin medical university cancer institute &amp; hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xin Yao, MD</last_name>
      <phone>0086-22-23340123</phone>
      <email>yaoxin1969@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Xin Yao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1.</citation>
    <PMID>19487381</PMID>
  </reference>
  <reference>
    <citation>Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010 Jul;66(2):357-71. doi: 10.1007/s00280-009-1170-y. Epub 2009 Dec 5. Review.</citation>
    <PMID>19967539</PMID>
  </reference>
  <reference>
    <citation>Neri B, Vannini A, Brugia M, Muto A, Rangan S, Rediti M, Tassi R, Cerullo C. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients. Int J Urol. 2013 May;20(5):478-83. doi: 10.1111/j.1442-2042.2012.03204.x. Epub 2012 Nov 1.</citation>
    <PMID>23113655</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <last_update_submitted>February 27, 2016</last_update_submitted>
  <last_update_submitted_qc>February 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Jun Guo</investigator_full_name>
    <investigator_title>Director of department of renal cancer and melanoma</investigator_title>
  </responsible_party>
  <keyword>metastatic renal cell carcinoma</keyword>
  <keyword>sunitinib</keyword>
  <keyword>schedule 2weeks on/1 week off</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

